Automate Your Wheel Strategy on NTRA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTRA
- Rev/Share 15.4291
- Book/Share 9.1276
- PB 24.9441
- Debt/Equity 0.1475
- CurrentRatio 3.2744
- ROIC -0.2405
- MktCap 31492925280.0
- FreeCF/Share 0.682
- PFCF 336.5887
- PE -101.0215
- Debt/Assets 0.1014
- DivYield 0
- ROE -0.2507
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NTRA | Citigroup | -- | Buy | -- | $300 | Jan. 7, 2026 |
| Resumed | NTRA | Morgan Stanley | -- | Overweight | -- | $265 | Dec. 2, 2025 |
| Upgrade | NTRA | BNP Paribas Exane | Underperform | Neutral | -- | $172 | Oct. 27, 2025 |
| Resumed | NTRA | Wells Fargo | -- | Equal Weight | -- | $175 | Sept. 22, 2025 |
| Initiation | NTRA | RBC Capital Mkts | -- | Outperform | -- | $251 | March 13, 2025 |
| Initiation | NTRA | Barclays | -- | Overweight | -- | $200 | Jan. 23, 2025 |
News
Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Natera, Inc. (NASDAQ:NTRA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Alexey Aleshin - GM Oncology, CMO Solomon Moshkevich - President, Clinical Diagnostics John Fesko - President and Chief Business Officer Conference Call Participants Doug Schenkel - Wolfe Research Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Baird Daniel Brennan - TD Cowen Dan Leonard - UBS Subbu Nambi - Guggenheim Operator Welcome everyone to Natera's 2024 Fourth Quarter …
Read More
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients with stage I-III NSCLC with resectable or unresectable disease in the surveillance setting. It expands upon preexistin.
Read More
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for colon cancer, rectal cancer, and merkel cell carcinoma (MCC). In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in.
Read More
About Natera, Inc. (NTRA)
- IPO Date 2015-07-01
- Website https://www.natera.com
- Industry Medical - Diagnostics & Research
- CEO Steven Leonard Chapman
- Employees 4424